Orpha Labs AG Announces the Initiation of a Phase III Trial Evaluating ORL-101 for Treatment of Leukocyte Adhesion Deficiency Type II
 
Orpha Labs AG is working with investigators to switch patients from a compassionate use study initiated last year to this Phase III study.

Feb 23, 2022, 08:00 ET